ViaCell Obtains License to Oocyte Cryopreservation
By Biotechdaily staff writers
Posted on 29 Aug 2003
A worldwide license for the use of technology to cryopreserve unfertilized human oocytes has been obtained by ViaCell, Inc. (Boston, MA, USA) from Gamete Technology, Inc. (N. Kingston, RI, USA) and Massachusetts General Hospital (MGH, Boston, USA). Posted on 29 Aug 2003
The patented technology is designed to help freeze, store, and later fertilize oocytes for use in in vitro fertilization (IVF) around the world. The technology is the result of an eight-year development effort led by scientists at MGH. By freezing eggs before cancer treatment or earlier in life when egg quality is higher, a woman may be able to retain her ability to become pregnant and have a child many months or even years later. ViaCell also offers umbilical cord blood stem cell preservation services through a subsidiary called Viacord.
"This agreement with Gamete Technology positions ViaCell as a leader in the development of oocyte cryopreservation services, which has the clear potential to be one of the most significant advances in reproductive medicine since the introduction of IVF,” said Marc Beer, chairman and CEO of ViaCell.
Related Links:
ViaCell
Massachusetts General Hospital
Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Blood-Based Protein Biomarker Solution for Alzheimer's Disease
BG-DTi2000.
Automated Urinalysis Solution
UN-9000
New
Drug Testing Assays
Atellica DT 250 Analyzer
